Alchemia reaps $4.4m from R&D Tax Incentive
27 February, 2013 by Tim DeanAlchemia (ASX:ACL) has received a payout under the R&D Tax Incentive scheme that has principally covered expenses related to phase III clinical trials.
AtCor signs $800K contract expansion
25 February, 2013 by Tim DeanAtCor Medical (ASX:ACG) has expanded an existing contract to supply its SphygmoCor diagnostic to the tune of $800,000.
Industry comments on ANZTPA’s joint framework
25 February, 2013 by AusBiotechAusBiotech has made a submission on behalf of the biotechnology industry to the Australia New Zealand Therapeutic Products Agency’s (ANZTPA) discussion paper.
AtCor swings to profit
22 February, 2013 by Dylan Bushell-EmblingAtCor Medical (ASX:ACG) has reported its second ever half-year profit for 1H13 thanks to revenue growth and cost-cutting.
AusBiotech commends Productivity Commission’s draft report on compulsory licensing of patents
21 February, 2013 by AusBiotechAusBiotech has commended the “thorough work of commission and its December 2012 ‘Draft Report’ on Compulsory Licensing of Patents”.
Movers & shakers: Another Farrell to head ResMed
21 February, 2013 by Tim DeanMick Farrell, son of Dr Peter Farrell, will take over as CEO of ResMed while his father transitions to non-executive chairman.
PolyActiva $9.2m cash injection
20 February, 2013 by Tim DeanPolyActiva has raised $9.2m to further the development of its polymer drug delivery technology platform.
Phosphagenics working on topical opioid patch
20 February, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) will bring a new product to trials after preclinical research showed oxycodone delivered with its TPM tech can provide pain relief without entering the blood.
Patent review bonanza has industry under siege
20 February, 2013 by Dr Anna Lavelle, CEO, AusBiotechContinual government reviews of the intellectual property system are creating uncertainty in the life sciences industry that could hurt its future success.
Industry applauds Labor policy to aid innovation
19 February, 2013 by Tim DeanLabor announced yesterday its long-awaited policy on jobs and innovation, offering several reforms aimed at aiding innovative companies and biotechs.
Novogen stocks soar following successful study
18 February, 2013 by Tim DeanNovogen (ASX:NRT) stocks have soared over 200% following a study that found its experimental drug CS-6 can kill not only cancer cells but also cancer stem cells.
Movers & shakers: Alchemia appoints new CEO
18 February, 2013 by Tim DeanAlchemia has appointed former Chief Financial Officer Charles Walker to the post of Chief Executive after Peter Smith stepped down following the failed Audeo Oncology demerger.
Gene patent upheld by Federal Court
18 February, 2013 by Tim DeanThe Federal Court has ruled in favour of Myriad Genetics and its patent of mutations in the BRCA1 gene, although some have expressed concern at the result.
Industry leaders’ views needed in the 2013 AusBiotech Industry Position Survey
18 February, 2013 by AusBiotechAusBiotech invites industry leaders to participate in the annual CEO Industry Position Survey 2013.
Sirtex posts another boost in sales and profit
14 February, 2013 by Tim DeanSirtex (ASX:SRX) has seen sales of SIRSpheres increase by 30.5% and net profit increase by 27.6% to $7.8 million in its half-year results.
